AsiaRealEstateDirectory.com is a one for all you need to know about asia real estate market. Home buyers and real estate investors find your real estate agents, property for sale , property developement companies, property management in asian country of your interest.

Tips for Finding the Best Real Estate Agents in Bangkok, Thailand

July 22nd, 2012 10:44 pm

Everyone knows that Real Estate is big business, and many people are trying to get their own part of the action by looking to new places around the world to build on. In the Far East there is no bigger market than Thailand real estate, in particular in Bangkok. Bangkok is a hugely popular destination for tourists and is easy to get to from all parts of the world; an increasing number of people are looking to live in Bangkok as well as venture there on holiday.

If you are planning to buy a house or property in Bangkok then Bangkok real estate agents are your best sources of information. You just have to make sure that you find the best agents so that you can also find the best property for you and your family. Keep reading this following article and you can find out your answer.

1. Experience

The first thing that you need to look for in your potential Bangkok real estate agents is experience. You need to know how long they’ve been doing their job and how many clients they’ve helped. This will give you an idea on how well they are able to do their job and how able they are to find you the best property in Bangkok.

2. Familiarity with the Area

There is no point in hiring a real estate agent if they are not familiar with the place. You have to make sure that with the experience they have, they also have extensive knowledge of Bangkok.

Bangkok real estate agents that are explicitly familiar with the area will help you get the best property on a beautiful location and within the budget that you have. They also must have an in-depth knowledge on the current market condition so that they can give you the best options to choose from.

3. Cost and Agreements

You should discuss how much it will cost you when you decide to hire a Bangkok real estate agent. It is better that you put this matter out in the open at the start of the meeting so that you can immediately know the expenses that you’ll be incurring. Most Bangkok real estate agents are open to negotiation and this will be a good time to discuss that before moving forward.

You also have to know the agreements or policies that they have, to avoid any disputes in the future. There have been a lot of misunderstandings with clients and real estate agents due to the fact that policies were not clearly discussed. To avoid this, you have to make sure that your agent clarifies these essential things before conducting business.

ADHD Treatments: Treatment for Attention Deficit Disorder

July 20th, 2012 11:08 pm

The most effective ADHD treatment strategy involves a combination of pharmacological and behavior modification therapies. The American Academy of Pediatrics (AAP) guidelines on ADD treatment recommends this multi-modal approach. The success of this, or any ADHD treatment protocol, depends on an accurate ADD diagnosis and a clear understanding of the child’s primary ADHD symptoms and associated behaviors.

ADHD Treatments – An Overview

Education of the parent and child about ADHD (see What is ADD, ADHD?) and the ADHD treatment strategy is imperative for long-term treatment success. Parents must then communicate with their child’s school personnel about ADHD and their child’s ADD treatment. Parents, clinical personnel, and school staff must work as a team to support the child and his unique needs to ensure treatment success and behavior modification achievement.

Pharmacological ADHD Treatment

Physicians most commonly prescribe an amphetamine or other stimulant medication as part of ADHD treatment strategy. Although using a stimulant medication for a condition associated with hy

peractivity might seem strange, these drugs actually calm the child with ADHD, increasing focus and reducing impulsive behavior. These ADHD medications come in various forms, such as a skin patch, pill, capsule, and liquid. Manufacturers produce some of these medications in long lasting, fast acting, or extended release formulations.

When physicians tell parents that they will prescribe an amphetamine for their child, they often express concerns about drug dependence; however, studies have shown that these drugs do not cause dependence when used properly.

Therapeutic Behavior Modification ADHD Treatment

The AAP guidelines encourage, but do not mandate, the adjunct use of behavior modification therapy for ADHD treatment in both adults and children. Children with the condition often have comorbid conditions, such as general anxiety disorder, oppositional defiant disorder, and obsessive-compulsive disorder. Behavioral therapy can treat some aspects of these conditions, enhancing the success of the pharmacological aspect of treatment.

Ongoing Treatment for Attention Deficit Disorder

Stimulant medications, such as amphetamine or methylphenidate continue to provide benefit when used as treatment for attention deficit disorder in children and teens. Parents need not worry that the use of stimulant drugs will increase the risk that their child will abuse drugs later. Actually, studies have indicated that children and teens with the ADHD that used stimulant drugs as treatment for attention deficit disorder were less likely to abuse drugs and alcohol later.

Final ADHD Treatment Considerations

One key element in effective ADHD treatment involves parents helping their children and teens implement the skills and behavior modification tools provided to them by the behavioral therapist. The level of involvement required is hard work, but it will pay off in the long run.

Long-term Testing Requirement for Psychiatric Drugs Abandoned Due to Big Pharma Pressure on the FDA

July 20th, 2012 6:31 am

The bipolar medication lithium is so toxic that it often causes major kidney damage, yet most patients must use it for lifetime maintenance of manic-depressive disorder. Similarly, schizophrenics often spend lifetimes on neuroleptics with long-term side effects such as tardive dyskinesias, or uncontrollable movement of the face, tongue, lips and extremities.

The point here? Side effects almost always go hand-in-hand with taking a medication for a long duration in order to treat a chronic condition. With that in mind, it seems outrageous that on Oct. 25, 2005, a panel voted to defeat the FDA’s proposal to extend pre-approval testing of psychiatric drugs from two short-term studies to six-month trials. In layman’s terms, psychiatric drugs will not be tested for a long enough time to determine their safety for long-term use before they are approved. Now, they can be tested for as little as two weeks, then given the stamp of safety approval by the FDA after which they will be used for years, if not decades, on unsuspecting patients.

In a Sept. 26 memo, Dr. Thomas P. Laughren, acting director of the FDA’s Division of Psychiatry Products, gave solid reasons for the FDA’s desire to extend its required testing time. In fact, he begins the memo with a simple fact that makes the need for long-term testing clear: “Most psychiatric illnesses are chronic.” He later goes on to explain that current short-term testing methods advocate stopping treatment of subjects who are responding to the drug after only a few weeks, something that would be considered “ethically questionable” in actual clinical treatment. In other words, real-world patients with mental disorders may have to stay on these drugs for months, years, decades and possibly even a lifetime, so why should clinical testing be limited to the short term?

The current short-term tests also present a problem for psychiatrists who are prescribing a newly-approved drug. As Dr. Laughren explains, “Since most treatment guidelines for chronic psychiatric illnesses recommend continuing patients for four to six months or longer after response during short-term treatment, clinicians have generally not had a sufficient evidence base (from pre-approval studies) to support what is the standard practice of drug treatment of psychiatric illnesses.”

When a psychiatric drug first hits the market, prescribing physicians are largely left in the dark about treatment issues after a patient stays on the medication longer than the six to 12 weeks tested during approval trials. Yes, the FDA generally asks for longer-term studies to be completed after approval, but it can be years before this is done. During this time patients are put at risk for side effects that did not emerge in the short pre-approval studies.

How Big Pharma overrules the FDA

Though Dr. Laughren rightly petitioned for testing standards to change, Big Pharma once again flexed its muscles and defeated the FDA’s acting director and other supporters of longer safety testing requirements. Pharmaceutical industry executives from Merck, Wyeth and Eli Lilly gathered with academic researchers and presented the 11-member Psychopharmacological Drugs Advisory Committee with 15 presentations, all against extending the duration of pre-approval trials to six months.

Their argument? According to Eli Lilly’s David Michelson, executive director for neuroscience medical research, half of all patients switch psychiatric medications after three months of treatment, with the figure reaching as high as 70 percent after six months. According to this logic, conducting six-month pre-approval tests will not benefit enough psychiatric patients to warrant the policy change. In other words, Big Pharma is saying we should ignore the potential health risks posed to psychiatric patients who take these drugs on a long-term basis because they don’t make up a large consumer group. This perspective is alarming in itself, but given the scandals surrounding Vioxx and other prescription drugs, it comes as no surprise.

The facts are clear: Mental illness is presently an epidemic in modern society, a result of our chronic malnutrition and ingestion of metabolic disruptors (ingredients that disrupt normal brain function, such as refined sugars, trans fatty acids, chemical sweeteners, artificial colors, etc.). According to statistics from the National Institute of Mental Health, about one in five American adults suffer from a diagnosable mental illness.

To make matters worse, our population’s desire for “magic pill” solutions has made us look to chemical cures for nutritionally- and environmentally-based problems. Because of this trend, drugs that we don’t fully understand are being prescribed to an ever-increasing percentage of our population. The long-term effects of this could be disastrous.

In this case, the FDA tried to take a positive step in protecting the public, but failed under the pressure from Big Pharma. It’s now up to concerned consumers like you to make your voice heard. Tell the FDA that you want psychiatric medication adequately tested, no matter what Big Pharma says.